Trial Profile
Complement C5 Antibodies for decreasing brain injury after aneurysmal Subarachnoid Hemorrhage: safety and proof-of-concept
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2022
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Aneurysm; Subarachnoid haemorrhage
- Focus Proof of concept; Therapeutic Use
- Acronyms CLASH
- 11 Feb 2022 Trial design presented at the International Stroke Conference 2022
- 20 Sep 2021 Status changed from recruiting to completed.
- 26 Jun 2018 New trial record